Coghill AE, Proietti C, Liu Z, et al. - Given seropositivity for Epstein–Barr virus (EBV) is seen in almost all children in Burkitt lymphoma–endemic areas but disease development is reported in only a small percentage, an explanatory cofactor could be the difference in EBV-directed immunity, and to gain insight into this topic, researchers performed this study including 150 Burkitt lymphoma cases and 150 controls, from whom they analyzed serum samples using a protein microarray that measured IgG and IgA antibodies against 202 sequences across the entire EBV proteome. They used unpaired t tests to evaluate the difference in the EBV-directed antibody repertoire between Burkitt lymphoma cases and controls. Findings revealed changed anti-EBV serologic profile in patients with Burkitt lymphoma, with strong rises evident in 33 of the measured anti-EBV IgG antibodies vs disease-free children. They noted that Burkitt lymphoma–related IgG rises were strongest for EBV proteins implicated in viral replication and antiapoptotic signaling. Particularly, ORs ≥ 4 were noted for BMRF1 (early antigen), BBLF1 (tegument protein), BHRF1 (Bcl-2 homolog), BZLF1 (Zebra), BILF2 (glycoprotein), BLRF2 [viral capsid antigen (VCA)p23], BDLF4, and BFRF3 (VCAp18).